How much impact does osimertinib have on the survival of patients with advanced lung cancer?

Osimertinib has a significant impact on the survival of patients with advanced lung cancer, specifically in the following aspects:

Multiple clinical trial data show that osimertinib can significantly prolong the survival of patients with EGFR mutation-positive non-small cell lung cancer. For example, in first-line treatment, the median progression-free survival (PFS) of osimertinib is approximately 18.9 months, and the median overall survival (OS) can exceed 30 months. For patients who develop T790M mutations after treatment with first- or second-generation EGFR-TKIs, the median overall survival of osimertinib as second-line treatment can reach about 26.8 months.

In real-world applications, osimertinib has also shown the effect of prolonging patient survival. Some patients have survived for more than 3 years after taking osimertinib, and in some cases the survival time has even reached 12 years. Of course, these cases are relatively rare and are affected by a variety of factors.

A patient's response to osimertinib is affected by the type of EGFR gene mutation. For example, patients with specific sensitizing mutations may be more sensitive to osimertinib and thus experience longer survival.

The patient's overall health is also an important factor affecting the efficacy of osimertinib. Patients in better physical condition may be better able to tolerate treatment and thus survive longer. Whether to receive other concomitant treatments (such as chemotherapy, immunotherapy, etc.) will also affect the patient's survival. Comprehensive treatment strategies often lead to better treatment results.

Although osimertinib can significantly prolong patient survival, most patients will eventually develop drug resistance. The development of drug resistance will reduce the efficacy of osimertinib and thus affect the survival of patients.

Osimertinib may produce some side effects during use, such as rash, diarrhea, fatigue, loss of appetite, etc. These side effects may affect the patient's quality of life and even require adjustments to the treatment plan.